Research - Since our initial report on Pharmacyclics (PCYC) on February 11, shares of the oncology company have returned almost 52%. Pharmacyclics’ relative underperformance to the NASDAQ … Continue Reading
Read NowResearch - Since we last profiled Cubist Pharmaceuticals (CBST) in August, shares of the antibiotics company have posted a somewhat muted performance, rising less than 8% versus … Continue Reading
Read NowResearch - Progenics Pharmaceuticals (PGNX) listed a new trial on clinicaltrials.gov on Monday that supports the PGNX long thesis. The stock has a had a nice run this … Continue Reading
Premium: Read NowResearch - Although the stock is getting away from us as we await feedback from the company (more below), for those not already involved, Progenics (PGNX) is … Continue Reading
Premium: Read NowResearch - CEO Jeremy Levin may be gone from Teva (TEVA), but it’s clear that while his tenure was short, his legacy may be meaningful. The challenge … Continue Reading
Read NowResearch - In the biotechnology sector, innovation can come in one of a few forms, including novel drugs or novel ways to deliver existing drugs. BioDelivery Sciences … Continue Reading
Premium: Read NowResearch - This article was published for PropThink’s Premium members on Friday, November 22. Hologic (HOLX) gapped up last Thursday morning after activist investor Carl Icahn reported … Continue Reading
Read Now
